Patent Issued for Organic compositions to treat HSF1-related diseases (USPTO 12091661).

A patent has been issued to Arrowhead Pharmaceuticals Inc. for organic compositions that can be used to treat HSF1-related diseases, such as cancer and viral diseases. HSF1 is a heat shock factor that regulates the heat shock response in the body. The patent describes RNAi agents that can target and reduce the expression of HSF1, which may be beneficial in treating various types of cancer. The patent also includes information about the composition and structure of the RNAi agents. [Extracted from the article]